Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant Targeted Molecular Therapy Before Renal Surgery.

Sumi Dey1, Henry N Peabody1, Sabrina L Noyes1

  • 1Spectrum Health, 145 Michigan Street NE, Grand Rapids, MI 49503, USA.

The Urologic Clinics of North America
|April 17, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of Cellular Signaling by CUL5 is Dependent on Its Neddylation Status.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology·2026
Same author

Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy.

Cancer·2026
Same author

Location matters: Reduced detection of csPCa in transition zone versus peripheral zone PI-RADS lesions.

Urologic oncology·2026
Same author

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Outcomes After Initial Noninterventional Management of Clinical Stage cT1b Renal Masses.

European urology open science·2025
Same author

Utilization of radical nephrectomy for patients with clinical stage T1 renal masses: Evaluation of opportunities for quality improvement.

Urologic oncology·2025

Neoadjuvant targeted molecular therapy shows promise for metastatic renal cell carcinoma patients. This approach may reduce tumor burden, prevent metastasis, and improve survival, potentially enabling less invasive surgeries.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) presents significant treatment challenges.
  • Current treatment strategies aim to control disease and improve patient survival.
  • Neoadjuvant therapy is increasingly explored to optimize surgical outcomes and systemic control.

Purpose of the Study:

  • To evaluate the potential benefits of neoadjuvant targeted molecular therapy in select patients with metastatic renal cell carcinoma.
  • To explore how neoadjuvant therapy can reduce tumor burden, prevent metastasis, and enhance overall survival.
  • To assess the impact of neoadjuvant therapy on surgical approaches, including partial nephrectomy and thrombectomy.

Main Methods:

  • This study focuses on the conceptual framework and potential applications of neoadjuvant therapy.
Keywords:
Locally advanced renal cell carcinomaNeoadjuvantPartial nephrectomyPreoperativeTargeted therapy

Related Experiment Videos

  • It reviews the proposed mechanisms by which targeted molecular agents may impact tumor characteristics.
  • The analysis considers outcomes such as tumor size reduction, complexity, and resectability.

    • Main Results:

    • Neoadjuvant therapy may reduce tumor size and complexity, facilitating less radical surgical interventions.
    • It has the potential to downstage tumor thrombus, aiding in successful thrombectomy.
    • Selected patients may experience improved resectability of initially unresectable tumors.

    Conclusions:

    • Neoadjuvant targeted molecular therapy offers potential benefits for select metastatic renal cell carcinoma patients.
    • Further clinical trials are essential to validate these benefits and define optimal patient selection criteria.
    • Investigating renal function, oncological, and survival outcomes is crucial for each active agent.